S&P Biotech SPDR (XBI)
$97.09 0.17 (0.18%)
19:59 EST XBI Stock Quote Delayed 15 Minutes
Previous Close $97.09
Market Cap 5.25B
PE Ratio -
Volume (Avg. Vol.) 2.05M
Day's Range 95.99 - 97.54
52-Week Range 72.97 - 98.79
Dividend & Yield 0.23 (0.23%)
XBI Stock Predictions, Articles, and S&P Biotech SPDR News
- From InvestorPlace
- From the Web
Biotech stocks are leading the charge in this bull market. And last week's drop is a golden opportunity for buying these three beauties.
Biotechnology investors have turned the equal-weight SPDR S&P Biotech ETF (XBI) into one of the largest sector plays. Is it right for you?
The biotech trade is always a momentum bet, and currently Wall Street is betting it will go up. I can use this play in XBI for free income.
Investors fear Amgen (AMGN) is a falling knife after dropping on earnings. Use that fear to sell puts for income in AMGN stock.
The SPDR S&P Biotech ETF is forming a bull flag. Here's how to play biotech stocks for profit in XBI.
Biotech stocks, including Celgene, are pulling back. CELG stock is one of the best dip-buying opportunities of the bunch.
ETFs should not move 11% in four days. The IBB just did that, so I will short it with no money out of pocket. Bet against the herd mentality.
XBI hit a new 52-week high of $76.60 on Tuesday before easing back slightly to about $75. And I'm opting to employ one of my preferred bullish strategies here.
Biotech stocks are quietly climbing higher. Here's how to trade the SPDR S&P Biotech (ETF) (XBI) before its seemingly imminent pop.
Like other leveraged ETFs, Direxion Daily S&P Biotech Bear 3X Shares (LABD) seduces with big potential gains when biotech stocks drop.
Biotech stocks are making a comeback. Use this bullish XBI play to capitalize on continued strength in the sector.
Biotech stocks have retraced to an attractive buy point. Consider these three plays on XBI, CELG and AMGN.
Biotech stocks and ETFs like iShares' IBB and SPDR's XBI were hammered Wednesday on Donald Trump's drug pricing comments. Opportunity knocks.
Biotech stocks have gained the wind, but the SPDR S&P Biotech (ETF) (XBI) hasn't yet caught up with the market. That's going to change soon.
The biotech stock pop is fading, but opportunity lurks for bulls and bears, and you can use the XBI ETF to make some money on its next move.
Biotech stocks remain under accumulation post-election. Play XBI on the cheap to profit from the expected continued upside.